Breaking News

The firm signed four new distribution deals to spread its products into more than a dozen new markets.

Deciphering Developmental Disorders study researchers estimated the portion of recessive coding diagnoses among patients of European and Pakistani ancestry.

Three studies encompassing dozens of ancient genomes are offering a closer look at complex historical population spread in North, Central, and South America.

The firm saw strong growth in respiratory illness assays and lead testing, which was offset by a decline in C. difficile testing.

The companies plan to study the current utility and understanding of NGS and precision medicine, and will provide educational programs in underserved areas.

Through their joint venture, Berry and Prenetics aim to offer a range of direct-to-consumer genetic testing services to the Chinese market.

Fresh off its August IPO, the company reported $2.8 million in revenue for the quarter, up from $2.7 million a year ago.

The company accessioned approximately 78,000 samples in Q3 2018, up 95 percent from the year-ago quarter when it accessioned 40,000 samples..

MDx revenues increased 3 percent to $158.0 million, but excluding non-recurring royalty revenue in the prior-year period, MDx revenues increased 10 percent.

The investigators showed that template-free Cas9 editing is capable of repair to a predicted genotype, allowing for correction of disease-associated mutations.

Researchers found that combining tumor and cancer cell line data with their MAGNETIC analysis approach could enhance drug response predictions.

The German molecular diagnostics firm recently completed a capital increase with subscription rights for existing shareholders, grossing €22.3 million.

The genetic testing firm said the revenue growth was driven by a 37 percent increase in the number of billable tests delivered in the quarter.

Under the agreement, Expedeon will give Quanterix access to its CaptSure immunoassay products along with its Lightning-Link antibody labeling technology.

The company attributed the growth to increasing global demand for breast cancer testing, and growing demand and reimbursement for its prostate test.

The firm saw 60 percent revenue growth in molecular diagnostics, including 88 percent growth in its Solana system.

Myriad CEO Mark Capone said earnings during the quarter exceeded expectations based on strong volume growth from hereditary cancer and new products.

The NxClinical software integrates copy number, sequence variant, and allelic change information obtained from microarray and NGS technologies.

Researchers investigated the possibility of picking up intra-tumor genetic heterogeneity in tumor exomes, identifying false-positives and technical noise.

Stratec is producing the microfluidic chips for Vortex' VTX-1 system, which enables the enrichment and isolation of circulating tumor cells.

The firm's full fiscal year revenues were also up, 32 percent as reported, or about 6 percent on a currency-neutral basis.

A re-analysis of genomic tests for 309 children with epilepsy altered diagnoses for more than a third of patients with a previously reported genetic variant.

The partners said they have agreed to work together on projects in a range of diseases, as well as establish research alliances with groups in China and Africa.

Total revenues were down due to lower assay revenues, which shrank 11 percent from a year ago. Sample-to-answer molecular product revenues grew 15 percent.

Given that genetic susceptibility to schizophrenia is highly polygenic, the researchers found that the risk scores had some utility as prognostic biomarkers.

Pages

Researchers in the UK and Australia uncover genetic links between BMI and depression, the Guardian reports.

The Verge details the account of an academic who alleges her university retaliated against her after she complained of sexual harassment by her supervisor.

The New York Times writes that natural history museums are helping round out genetic studies with older specimens.

In PNAS this week: artemisinin resistance mutations in malaria parasites, ant-plant interactions over time, and more.